EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Clinical management strategies for cytokine release syndrome and their impact on CAR T-cell efficacy in lymphoma

Kaihang Shi, Xueyan Sun, Gaoxiang Wang

International Immunopharmacology · 2026-12 · 190 · 117465

DOI: 10.1016/j.intimp.2026.117465 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2026-12. Verfasst von Kaihang Shi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. Hauptthemen laut MEDLINE: Cytokine Release Syndrome, Immunotherapy, Adoptive, Lymphoma. Die Arbeit nennt 102 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T-cell (CAR-T) therapy has significantly advanced the treatment of relapsed/refractory (R/R) lymphoma. However, its broader clinical application is often limited by cytokine release syndrome (CRS), a major immune-mediated complication. Because the in vivo expansion of CAR-T cells drives both tumor clearance and CRS, addressing this toxicity without impairing anti-tumor efficacy remains a critical clinical necessity. This review comprehensively evaluates current and emerging CRS management strategies across the entire treatment process. First, we explore proactive pre-infusion measures, such as bridging therapies and lymphodepletion regimens, which help mitigate baseline inflammatory risks. Next, we outline standard-of-care treatments for established CRS, focusing on the optimized dosing of corticosteroids and cytokine-blocking agents. We then discuss novel investigational approaches, including targeted kinase inhibitors and emerging cytokine-directed antibodies, that show potential to decouple inflammatory signaling from CAR-T cytotoxicity. Overall, our findings highlight that effective CRS management relies on a comprehensive strategy that optimizes established treatments and integrates novel targeted therapies. When adapted to individual clinical profiles, these customized approaches can effectively control systemic inflammation while potentially preserving anti-tumor efficacy, though more prospective trials are needed to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytokine Release SyndromeImmunotherapy, AdoptiveLymphomaHumansReceptors, Chimeric AntigenAnimalsCytokines

Stichwörter der Autor:innen

CAR-TCytokine release syndromeImmunotherapyLymphomaPharmacotherapy

Substanzen

Receptors, Chimeric AntigenCytokines

Autor:innen und Institutionen

  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. Electronic address: gxwtjxy@126.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Shi, K., Sun, X., & Wang, G. (2026). Clinical management strategies for cytokine release syndrome and their impact on CAR T-cell efficacy in lymphoma. International Immunopharmacology, 190, 117465. https://doi.org/10.1016/j.intimp.2026.117465

Vancouver

Shi K, Sun X, Wang G. Clinical management strategies for cytokine release syndrome and their impact on CAR T-cell efficacy in lymphoma. International Immunopharmacology. 2026;190:117465. doi:10.1016/j.intimp.2026.117465

BibTeX
@article{Shi2026,
  author = {Shi, Kaihang and Sun, Xueyan and Wang, Gaoxiang},
  title = {Clinical management strategies for cytokine release syndrome and their impact on CAR T-cell efficacy in lymphoma},
  journal = {International Immunopharmacology},
  year = {2026},
  volume = {190},
  pages = {117465},
  doi = {10.1016/j.intimp.2026.117465}
}
Kostenlos starten →